MedTrace Logo

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

NCT05285904 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2026-04-14

No results posted yet for this study

Summary

This is a multi-center, observational study carried out in Switzerland that aims to describe the effects of Ofatumumab in a setting of routine medical care.

Conditions

Interventions

OTHER

Ofatumumab

Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-12
Primary Completion
2026-02-04
Completion
2026-02-04

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05285904 on ClinicalTrials.gov